QCM
DSGN icon

Quantinno Capital Management’s Design Therapeutics DSGN Stock Holding History

Quantinno Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150K Buy
+14,128
New +$143K ﹤0.01% 3230

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Quantinno Capital Management's DSGN Position: Q1 2026 in Review

Quantinno Capital Management opened a new position in Design Therapeutics (DSGN) in Q1 2026: 14,128 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #3230 among its holdings.

125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Quantinno Capital Management held 14,128 shares of Design Therapeutics worth $150K as of Q1 2026.
  • Design Therapeutics was a new Quantinno Capital Management position in Q1 2026.
  • Design Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #3230 holding.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.